<DOC>
	<DOCNO>NCT00330915</DOCNO>
	<brief_summary>The purpose study help answer follow research question : If study drug Pemetrexed help patient rectal cancer ; If molecular biological parameter correlate respectively change due cytotoxic treatment Pemetrexed ; To evaluate adverse event</brief_summary>
	<brief_title>A Study Pemetrexed Folic Acid Given Before Surgery ( Neoadjuvant Treatment ) Patients With Rectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>prior therapy rectal cancer pathological/ cytological diagnosis adenocarcinoma rectum . Patients must operable rectal cancer amenable surgery . adequate organ function Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 sign inform consent least 18 year age surgically sterile , postmenopausal ( woman ) compliant medically approve contraceptive regimen 6 month treatment . concurrent administration antitumor therapy treatment within last 30 day drug receive regulatory approval indication time study entry serious concomitant systemic disorder previously complete withdrawn study pregnant breastfeed second primary malignancy history significant neurological mental disorder , include seizure dementia inability interrupt aspirin nonsteroidal antoinflammatory drug ( NSAIDs ) presence clinically relevant third space fluid collection control drainage procedure prior study entry inability unwillingness take folic acid , vitamin B12 dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>